Epidemiology and Prevention of Cervical Cancer in Indonesia, Malaysia, the Philippines, Thailand and Vietnam

被引:72
作者
Domingo, Efren J. [1 ]
Noviani, Rini [2 ,3 ]
Noor, Mohd Rushdan Md [4 ]
Ngelangel, Corazon A. [5 ]
Limpaphayom, Khunying K. [6 ]
Van Thuan, Tran [7 ]
Louie, Karly S. [7 ]
Quinn, Michael A. [8 ]
机构
[1] Univ Philippines, Dept Obstet & Gynecol, Coll Med, Philippine Gen Hosp, Manila, Philippines
[2] Directorate Gen Dis Control & Environm Hlth, Directorate Non Communicable Dis Control, Subdirectorate Canc Control, Jakarta, Indonesia
[3] Minist Hlth Republ Indonesia, Jakarta, Indonesia
[4] Hosp Sultanah Bahiyah, Dept Obstet & Gynaecol, Gynaecol Oncol Unit, Alor Star, Kedah, Malaysia
[5] Univ Philippines, Clin Epidemiol Unit, Dept Med, Philippine Gen Hosp, Manila, Philippines
[6] Chulalongkorn Univ, Fac Med, Dept Obstet & Gynaecol, Bangkok 10330, Thailand
[7] ICO, CERP, UNIC, Barcelona, Spain
[8] Royal Hosp Women, Oncol & Dysplasia Unit, Melbourne, Vic, Australia
关键词
Asia Pacific; Indonesia; Malaysia; Philippines; Thailand; Vietnam; HPV; Cervical cancer; Prevalence; Vaccine;
D O I
10.1016/j.vaccine.2008.05.039
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cervical cancer remains one of the leading causes of cancers in women from Indonesia, Malaysia, the Philippines, Thailand and Vietnam. High-risk human papillomavirus (HPV) types, particularly HPV-16 and 18, are consistently identified in cervical cancer cases regardless of geographical region. Factors that have been identified to increase the likelihood of HPV exposure or subsequent development of cervical cancer include young age at first intercourse, high parity and multiple sexual partners. Cervical cancer screening programs in these countries include Pap smears, single visit approach utilizing visual inspection with acetic acid followed by cryotherapy, as well as screening with colposcopy. Uptake of screening remains low in all regions and is further compounded by the lack of basic knowledge women have regarding screening as an opporunity for the prevention of cervical cancer. Prophylactic HPV vaccination with the quadrivalent vaccine has already been approved for use in Malaysia, the Philippines and Thailand, while the bivalent vaccine has also been approved in the Philippines. However, there has been no national or government vaccination policy implemented in any of these countries. (c) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:M71 / M79
页数:9
相关论文
共 39 条
[1]   Human papillomavirus infection among women in South and North Vietnam [J].
Anh, PTH ;
Hieu, NT ;
Herrero, R ;
Vaccarella, S ;
Smith, JS ;
Thuy, NT ;
Nga, NH ;
Duc, NB ;
Ashley, R ;
Snijders, PJF ;
Meijer, CJLM ;
Muñoz, N ;
Parkin, DM ;
Franceschi, S .
INTERNATIONAL JOURNAL OF CANCER, 2003, 104 (02) :213-220
[2]  
[Anonymous], 2007, IARC Scientific Publications
[3]  
Brown A, 2001, SEXUAL RELATIONS YOU
[4]  
CASTELLSAGUE X, 2007, VACCINE S3, V25
[5]   Risk factors for cervical cancer in Thailand:: A case-control study [J].
Chichareon, S ;
Herrero, R ;
Muñoz, N ;
Bosch, FX ;
Jacobs, MV ;
Deacon, J ;
Santamaria, M ;
Chongsuvivatwong, V ;
Meijer, CJLM ;
Walboomers, JMM .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (01) :50-57
[6]  
CURADO MP, 2005, CANC INCIDENCE 5 CON, V1
[7]   Human papillomavirus type 18 and other risk factors for cervical cancer in Jakarta, Indonesia [J].
de Boer, M. A. ;
Vet, J. N. I. ;
Azizz, M. F. ;
Cornain, S. ;
Purwoto, G. ;
van den Akker, E. W. M. ;
Dijkman, A. ;
Peters, A. A. W. ;
Fleuren, G. J. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 (05) :1809-1814
[8]   Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology:: a meta-analysis [J].
de Sanjose, Silvia ;
Diaz, Mireia ;
Castellsague, Xavier ;
Clifford, Gary ;
Bruni, Laia ;
Munoz, Nubia ;
Bosch, F. Xavier .
LANCET INFECTIOUS DISEASES, 2007, 7 (07) :453-459
[9]  
DEERASAMEE S, 1999, CANC THAILAND
[10]  
*DEP HLTH REP PHIL, 2005, 20052006 DEP HLTH RE